| Number: 02-0580 |
Principal Investigator: Tan, Benjamin |
| Title: A Feasibility Phase II Study of Gemcitabine with Docetaxel Followed by Concurrent 3-D Conformal Radiation plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers |
| Description: You may be asked to take part in this study if you have cancer of the gallbladder or pancreas, cholangiocarcinoma, or an ampullary cancer. This study will test the combination of two drugs called gemcitabine and docetaxel, followed three weeks later by radiation therapy and 5-Flourouracil (5-FU), a...MORE |
| ________________________________________________________________________ |
| Number: 03-1015 |
Principal Investigator: Strasberg, Steven |
| Title: A Randomized, Phase II, Study of TNFerade Biologic with 5-FU and Radiation Therapy for First Line Treatment of Unresectable Locally Advanced Pancreatic Cancer |
| Description: The primary purpose of this study is to assess the safety and effectiveness of giving TNFerade™ Biologic in combination with the standard of care treatment of 5-FU and radiation therapy to treat patients with locally advanced pancreatic cancer that cannot be removed with surgery....MORE |
| ________________________________________________________________________ |
| Number: 09-1397 |
Principal Investigator: Early, Dayna |
| Title: Familial Pancreatic Cancer Screening Program at Washington University |
| ________________________________________________________________________ |
| Number: 09-1497 |
Principal Investigator: Pai, Rish |
| Title: Significance of Direct Extension by Pancreatic Adenocarcinoma Into Regional Lymph Nodes |
| ________________________________________________________________________ |
| Number: 08-0584 |
Principal Investigator: Cao, Dengfeng |
| Title: Clinicopathologic and Immunohistochemical Study of Pancreatic Tumors and Their Mimickers |
| ________________________________________________________________________ |
| Number: 07-1196 |
Principal Investigator: Linehan, David |
| Title: Implications of Surgical Margin Status on Recurrence in the Remnant Pancreatic Gland for Pancreatic neoplasms |
| ________________________________________________________________________ |
| Number: 08-1092 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: You may be asked to take part in this study because you have solid tumor cancer that is either resistant to treatment or for which there is no known effective treatment. The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimu...MORE |
| ________________________________________________________________________ |
| Number: 07-0447 |
Principal Investigator: Picus, Joel |
| Title: Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Resistant Solid Malignancies |
| Description: You may be asked to participate in this study because you have cancer that has continued to grow following standard treatment, or because no standard treatment is available for your type of cancer.
The main purposes of this study are to learn about the safety of temsirolimus and pegylated liposom...MORE |
| ________________________________________________________________________ |
| Number: 07-0265 |
Principal Investigator: Hawkins, William |
| Title: Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients with Advanced Pancreas Cancer |
| Description: You may be asked to participate in this study if you have advanced pancreas cancer. The overall purpose of this research is to evaluate the side effects of an investigational medication, named IMP321, in patients being treated with gemcitabine. Gemcitabine is an antimetabolite (a class of drugs th...MORE |
| ________________________________________________________________________ |
| Number: P2C MC0547 |
Principal Investigator: Picus, Joel |
| Title: A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer (P2C# MC0547, NCI# 7602) |
| Description: The purpose of this study is to find out what effects, good and/or bad, AZD0530 has on advanced pancreas cancer. AZD0530 inhibits growth signaling in tumor cells and possibly inhibits spreading of tumor cells. These may be important targets in pancreatic cancer. AZD0530, given as a pill, is an in...MORE |
| ________________________________________________________________________ |
| Number: 09-0778 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cabazitaxel in Combination with Cisplatin Administered Every 3 Weeks in Subjects with Advanced Solid Malignancies |
| ________________________________________________________________________ |
| Number: 09-0401 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors |
| ________________________________________________________________________ |
| Number: 09-0015 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase I Investigation of MK-5108 and MK-5108 with Docetaxel in Patients with Advanced Solid Tumors |
| Description: This study is being done to test the safety of MK-5108 (the study drug), collect information on how your body responds to MK-5108, and find the highest dose of MK-5108 that can be given safely without serious side effects. This study will look at MK-5108 when it is given alone and when it is given w...MORE |
| ________________________________________________________________________ |
| Number: 06-0514 |
Principal Investigator: Baggstrom, Maria |
| Title: A phase Ib, multicenter, open-label, dose-finding study of patupilone administered intravenously every 3 weeks in combination with carboplatin AUC 6 in adult patients with advanced solid tumors |
| Description: You may be invited to join in a clinical research study to find out if the drug patupilone combined with carboplatin is safe and has beneficial effects in people who have advanced solid tumors who have progressed despite standard therapy or for whom no standard therapy exists or whom might benefit f...MORE |
| ________________________________________________________________________ |
